LLY

1,142.12

-0.21%↓

JNJ

236.71

+1.9%↑

ABBV

225.17

+1.13%↑

UNH

412.34

+1.63%↑

MRK

119.37

+0.12%↑

LLY

1,142.12

-0.21%↓

JNJ

236.71

+1.9%↑

ABBV

225.17

+1.13%↑

UNH

412.34

+1.63%↑

MRK

119.37

+0.12%↑

LLY

1,142.12

-0.21%↓

JNJ

236.71

+1.9%↑

ABBV

225.17

+1.13%↑

UNH

412.34

+1.63%↑

MRK

119.37

+0.12%↑

LLY

1,142.12

-0.21%↓

JNJ

236.71

+1.9%↑

ABBV

225.17

+1.13%↑

UNH

412.34

+1.63%↑

MRK

119.37

+0.12%↑

LLY

1,142.12

-0.21%↓

JNJ

236.71

+1.9%↑

ABBV

225.17

+1.13%↑

UNH

412.34

+1.63%↑

MRK

119.37

+0.12%↑

Accueil・Liste d'Actions・Immunocore Holdings PLC ADR

Immunocore Holdings PLC ADR

Fermé

28.48 3.04

Acheter Vendre

Résumé

Variation du prix de l'action

24h

Actuel

Min

27.59

Max

29.09

Chiffres clés
By Trading Economics
Revenu	43M 13M
Ventes	29M 107M
BPA	0.25
Marge bénéficiaire	12.139
Employés	524
EBITDA	16M 8.2M

Recommandations
By TipRanks
Recommandations	Achat
Prévisions sur 12 Mois	+134.36% upside

Dividendes
By Dow Jones
Prochains Résultats	6 août 2026

Statistiques du Marché
By TradingEconomics
Capitalisation Boursière	-11M 1.4B
Ouverture précédente	25.44
Clôture précédente	28.48

Immunocore Holdings PLC ADR Graphique

Les performances passées ne sont pas un indicateur fiable des résultats futurs.

Actualités Associées

9 juin 2026, 23:49 UTC

Market Talk

Nikkei May Fall Following Tech Stock Declines on Wall Street -- Market Talk

9 juin 2026, 23:45 UTC

Acquisitions, Fusions, Rachats

Correct: Sigma Healthcare: Has Engaged in Preliminary Discussions in Boots Sale Process

9 juin 2026, 23:44 UTC

Acquisitions, Fusions, Rachats

Sigma Healthcare Says No Certainty That Any Transaction Will Eventuate

9 juin 2026, 23:44 UTC

Acquisitions, Fusions, Rachats

Sigma Healthcare: Continuously Reviews Opportunities to Create Value For Shareholders

9 juin 2026, 23:43 UTC

Acquisitions, Fusions, Rachats

Sigma Healthcare: Has Engaged in Preliminary Discussions to Sell Boots

9 juin 2026, 23:35 UTC

Market Talk

Oil Rises on Escalating Supply Disruption Concerns -- Market Talk

9 juin 2026, 22:06 UTC

Acquisitions, Fusions, Rachats

Samsung: Element Has Expanded Rapidly Since 2022 Launch of AVITI

9 juin 2026, 22:05 UTC

Acquisitions, Fusions, Rachats

Samsung: Element to Speed Commercialization of Gene-Sequencing Products

9 juin 2026, 22:05 UTC

Acquisitions, Fusions, Rachats

Samsung: Additional Investment Makes It Largest Shareholder in Element

9 juin 2026, 22:05 UTC

Acquisitions, Fusions, Rachats

Samsung Electronics Raises Stake in Element Biosciences With $175 Million Investment

9 juin 2026, 20:51 UTC

Résultats

Micron, Marvell, Super Micro, Coherent, Smucker, and More Stocks That Explain Today's Market -- Barrons.com

9 juin 2026, 20:50 UTC

Market Talk

Financial Services Roundup: Market Talk

9 juin 2026, 20:50 UTC

Market Talk

Basic Materials Roundup: Market Talk

9 juin 2026, 20:09 UTC

Market Talk

Cryptocurrency Traders Look for Bitcoin Bottom -- Market Talk

9 juin 2026, 19:36 UTC

Market Talk

Cattle Climbs as Crude Oil Falls -- Market Talk

9 juin 2026, 19:32 UTC

Market Talk

Barclays Oil Price Outlook Contingent on Hormuz Reopening -- Market Talk

9 juin 2026, 19:25 UTC

Market Talk

U.S. Natural Gas Futures Slip in Rangebound Trade -- Market Talk

9 juin 2026, 19:00 UTC

Market Talk

Oil Settles Lower on Continued Hopes for Middle East Deal -- Market Talk

9 juin 2026, 18:52 UTC

Acquisitions, Fusions, Rachats

Warner Bros. Stock Hits a Low. Its Paramount Merger Return Is Getting Buzz. -- Barrons.com

9 juin 2026, 18:47 UTC

Market Talk

No World Cup Inflation Seen So Far in Mexico -- Market Talk

9 juin 2026, 18:37 UTC

Market Talk

Canada's Cooling Trade With the U.S. -- Market Talk

9 juin 2026, 18:27 UTC

Market Talk

Precious Metals Lower as Trump Vows Military Response -- Market Talk

9 juin 2026, 17:35 UTC

Market Talk

Treasury Yields, Dollar Briefly Rise on Trump's Iran Retaliation Threat -- Market Talk

9 juin 2026, 17:30 UTC

Market Talk

Trump Post on Apache Helicopter Causes Brief Spike in Oil -- Market Talk

9 juin 2026, 16:34 UTC

Market Talk

Cryptocurrency Weakness Follows Selling in Equities -- Market Talk

9 juin 2026, 16:20 UTC

Market Talk

Financial Services Roundup: Market Talk

9 juin 2026, 16:20 UTC

Market Talk

Basic Materials Roundup: Market Talk

9 juin 2026, 16:20 UTC

Market Talk

Acquisitions, Fusions, Rachats

Health Care Roundup: Market Talk

9 juin 2026, 15:28 UTC

Market Talk

Gold Futures Fall Further as Rate Fears Prevail -- Market Talk

9 juin 2026, 15:25 UTC

Market Talk

Oil Extends Losses, Falling More Than 3.5% -- Market Talk

Comparaison

Variation de prix

Immunocore Holdings PLC ADR prévision

Objectif de Prix

By TipRanks

134.36% hausse

Prévisions sur 12 Mois

Moyen 65.13 USD 134.36%

Haut 100 USD

Bas 33 USD

Basé sur 9 analystes de Wall Street proposant des objectifs de prix à 12 mois pour Microsoft Corp. au cours des 3 derniers mois.

Note du Consensus

By TipRanks

Achat

9 ratings

Achat

Maintien

Vente

Basé sur 9 qui ont noté l'action Microsoft Corp. au cours des 3 derniers mois.

Éléments financiers

Frais Généraux et Administratifs

Dépenses d'exploitation

Résultat avant impôt

Ventes

Coût des ventes

Marge brute des ventes

Charges d'intérêt sur la dette

EBITDA

Bénéfice d'exploitation

À Propos Immunocore Holdings PLC ADR

Immunocore Holdings plc, a commercial-stage biotechnology company, engages in the development of immunotherapies for the treatment of cancer, infectious, and autoimmune diseases. The company offers KIMMTRAK for the treatment of patients with unresectable or metastatic uveal melanoma. It also develops other programs for oncology, including tebentafusp that is in Phase 2/3 clinical trial to treat advanced cutaneous melanoma. In addition, the company's product pipeline comprises IMC-F106C, which is in a Phase 3 clinical trial to treat first line advanced cutaneous melanoma; and in a Phase 1/2 clinical trial in multiple tumor types, such as platinum resistant ovarian, non-small cell lung, and endometrial carcinoma. Further, it develops IMC-R117C, which is in phase 1 clinical trial to treat colorectal and gastrointestinal cancers; IMC-M113V, which is in phase 1 clinical trial to treat human immunosuppression virus; IMC-I109V, which is in a Phase I clinical trial in patients with chronic hepatitis B virus; IMC-T119C, which is in preclinical trial for multiple solid tumor cancers; IMC-P115C, which is in preclinical trial to treat multiple solid tumor cancers; and IMC-S118AI to treat type 1 diabetes and is in preclinical trial. Immunocore Holdings plc was founded in 1999 and is headquartered in Abingdon, the United Kingdom.